Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients

Pediatric Blood and Cancer

Volumn 57, Issue 2, 2011, Pages 191-198

  Dupuis, L Lee ^a,b   Boodhan, Sabrina ^a   Sung, Lillian ^a,c   Portwine, Carol ^d   Hain, Richard ^e   Mccarthy, Patricia ^f   Holdsworth, Mark ^g  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^f CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^g UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Antineoplastic induced nausea and vomiting; Antineoplastics; Chemotherapy induced nausea and vomiting; Emetogenicity; Nausea; Vomiting

Indexed keywords

ALTRETAMINE; AMIFOSTINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; BENDAMUSTINE; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; IMATINIB; METHOTREXATE; PROCARBAZINE; RECOMBINANT INTERLEUKIN 2; SEROTONIN 3 ANTAGONIST; STREPTOZOCIN; THIOTEPA; UNINDEXED DRUG;

ANTIEMETIC ACTIVITY; ANTINEOPLASTIC INDUCED NAUSEA AND VOMITING; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD CANCER; CHILDHOOD DISEASE; CLINICAL DECISION MAKING; CONSULTATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HIGH RISK POPULATION; HUMAN; MEDICAL SOCIETY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PEDIATRICS; PHASE 1 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; NAUSEA; NEOPLASMS; RISK ASSESSMENT; VOMITING;

EID: 79958791243     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23114     Document Type: Review

References (43)

1. Dupuis LL, Milne-Wren C, Cassidy M, et al. Symptom assessment in children receiving cancer therapy: The parents' perspective. Support Care Cancer 2010;18:281-299.
2. The ADAPTE Collaboration. January 20, 2009. <>. Accessed January 20, 2009.
3. Guyatt GH, Cook DJ, Jaeschke R, et al. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:123S-131S.
4. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. Br Med J 2008;336:924-926.
5. Multinational Association of Supportive Care in Cancer. November 30, 2008. Antiemetic Treatment Guidelines. <>. Accessed November 30, 2008.
6. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-109.
7. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology Guidelines for Antiemetics in Oncology: Update 2006. J Clin Oncol 2006;24:2932-2947.
8. National Comprehensive Cancer Network. 2008 November. Antiemesis v2.2008. In NCCN Clinical Practice Guidelines in Oncology National Comprehensive Cancer Network <>. Accessed 2008 November.
9. Dupuis LL, Maloney AM, Nathan PC, et al. Antiemetic selection for children receiving antineoplastics and/or radiotherapy. In: Lau E, editor. 2008-2009 drug handbook and formulary. Toronto: SickKids; 2008. pp. 246-251.
10. Children's Oncology Group. October 25, 2010. Supportive Care Guidelines. <>. Accessed October 25, 2010.
11. National Comprehensive Cancer Network. July 2. NCCN Clinical Practice Guidelines in Oncology, Antiemesis v.3. 2009. <>. Accessed July 2, 2009.
12. Berrak SG, Ozdemir N, Bakirci N, et al. A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy. Support Care Cancer 2007;15:1163-1168.
13. Holdsworth MT, Raisch DW, Frost J. Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 2006;106:931-940.
14. Pinkerton CR, Williams D, Wootton C, et al. 5-HT3 antagonist ondansetron-An effective outpatient antiemetic in cancer treatment. Arch Dis Child 1990;65:822-825.
15. Uysal KM, Olgun N, Sarialioglu F. Tropisetron in the prevention of chemotherapy-induced acute emesis in pediatric patients. Turk J Pediatr 1999;41:207-218.
16. Miyajima Y, Numata S, Katayama I, et al. Prevention of chemotherapy-induced emesis with granisetron in children with malignant diseases. Am J Pediatr Hematol Oncol 1994;16:236-241.
17. Hayes FA, Green AA, Casper J. Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: Response and toxicity. Cancer 1981;48:1715-1718.
18. Sumer T, Abu-Melha A, Maqbool G, et al. Dexamethasone as an antiemetic in children receiving cis-platinum. Am J Pediatr Hematol Oncol 1988;10:126-128.
19. Hewitt M, Cornish J, Pamphilon D, et al. Effective emetic control during conditioning of children for bone marrow transplantation using ondansetron, a 5-HT3 antagonist. Bone Marrow Transplant 1991;7:431-433.
20. Kusnierczyk N, Saunders EF, Dupuis LL. Outcomes of antiemetic prophylaxis in children undergoing bone marrow transplantation. Bone Marrow Transplant 2002;30:119-124.
21. Komada Y, Matsuyama T, Takao A, et al. A randomised dose-comparison trial of granisetron in preventing emesis in children with leukemia receiving emetogenic chemotherapy. Eur J Cancer 1999;35:1095-1101.
22. Saarinen UM, Hovi L, Makipernaa A, et al. High-dose thiotepa with autologous bone marrow rescue in pediatric solid tumors. Bone Marrow Transplant 1991;8:369-376.
23. Lafay-Cousin L, Hartmann O, Plouvier P, et al. High-dose thiotepa and hematopoietic stem cell transplantation in pediatric malignant mesenchymal tumors: A phase II study. Bone Marrow Transplant 2000;26:627-632.
24. Nahata M, Hui L, Koepke J. Efficacy and safety of ondansetron in pediatric patients undergoing bone marrow transplantation. Clin Ther 1996;18:466-476.
25. Holdsworth MT, Raisch DW, Duncan MH, et al. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. Ann Pharmacother 1995;29:16-21.
26. Dupuis LL, Lau R, Greenberg ML. Effectiveness of strategies for preventing acute antineoplastic-induced nausea and vomiting in children with acute lymphoblastic leukemia. Can J Hosp Pharm 1999;52:350-361.
27. Nguyen L, Fuller D, Lennon S, et al. I.V. busulfan in pediatrics: A novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 2004;33:979-987.
28. ESP Pharma. IV Busulfex (busulfan) injection product monograph. Edison, NJ: ESP Pharma; 2003. Report.
29. Aug 6. Clolar Full Prescribing Information. Genzyme <>. Accessed August 6, 2009.
30. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004;103:784-789.
31. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006;24:1917-1923.
32. Holdsworth MT, Raisch DW, Winter SS, et al. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron. Support Care Cancer 1998;6:132-138.
33. Parker RI, Prakash D, Mahan RA, et al. Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children. J Pediatr Hematol Oncol 2001;23:578-581.
34. Cancer Care Ontario. August 6, 2009. Management of Chemotherapy-induced Nausea and Vomiting. <>. Accessed August 6, 2009.
35. British Columbia Cancer Agency. August 6, 2009. Amsacrine. <>. Accessed August 6, 2009.
36. Dick GS, Meller ST, Pinkerton CR. Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. Arch Dis Child 1995;73:243-245.
37. Luisi FAV, Petrilli AS, Tanaka C, et al. Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma. Sao Paulo Med J 2006;124:61-65.
38. Sullivan MJ, Abbott GD, Robinson BA. Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children. N Z Med J 1992;105:369-371.
39. Relling MV, Mulhern RK, Fairclough D, et al. Chlorpromazine with and without lorazepam as antiemetic therapy in children receiving uniform chemotherapy. J Pediatr 1993;123:811-816.
40. Hinds PS, Gattuso JS, Billups CA, et al. Aggressive treatment of non-metastatic osteosarcoma improves health-related quality of life in children and adolescents. Eur J Cancer 2009;45:2007-2014.
41. Molassiotis A, Saunders MP, Valle J, et al. A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 2008;16:201-208.
42. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261-2268.
43. Kris MG. Why do we need another antiemetic? Just ask. J Clin Oncol 2003;21:4077-4080.